Tags

Type your tag names separated by a space and hit enter

Serological profile of patients with systemic sclerosis.
Postepy Hig Med Dosw (Online). 2014 Aug 18; 68:987-91.PH

Abstract

INTRODUCTION

The systemic sclerosis-associated autoantibodies include anti-centromere, anti-topoisomerase I (anti-topo I), anti-RNA polymerase III, anti-fibrillarin, anti-Th/To, and anti-PDGFR. A specific serological profile is connected with clinical manifestations and prognosis in systemic sclerosis (SSc).

OBJECTIVES

The aim of the study was to assess the serological profile in limited cutaneous and diffuse cutaneous SSc (lcSSc and dcSSc).

PATIENTS AND METHODS

87 (68 female and 19 male) consecutive SSc patients treated between 2006 and 2011 were assessed. Patients fulfilled the American College of Rheumatology classification criteria of SSc: 35 - dcSSc and 52 - lcSSc. The following marker antibodies were determined: anti-topo I, anti-centromere A and B (CENP A, CENP B), anti-RNA polymerase III (RP11, RP 155), anti-fibrillarin (U3RNP), anti- -NOR90, anti-Th/To, anti-PM-Scl-100, anti-PM-Scl-75, anti-Ku, anti-Ro-52, anti-PDGFR. The presence of antibodies was assessed using a test - EUROLINE Systemic Sclerosis Profile.

RESULTS

82 patients (94%) had positive antinuclear antibodies; anti-topo I - 29 patients; anti-CENP-A - 20 and anti-CENP-B - 20; anti-RP11 - 9 and anti-RP155 - 7; anti-U3RNP - 1; anti-NOR90 - 6; anti-Th/ To - 3; anti-PM-Scl-100 - 7; anti-PM-Scl-75 - 11; anti-Ku - 5; anti-Ro-52 - 23 patients. We found significant differences in prevalence of anti-topo I: 25/35 vs. 4/52 p=0.0000; anti-CENP A: 0/35 vs. 20/52 p=0.0001; anti-CENP B: 0/35 vs. 20/52 p=0.0001 between dcSSc and lcSSc.

CONCLUSIONS

Some antibodies in SSc, e.g. anti-topo I and anti-centromere, are useful in defining the clinical subset of disease and provide prognostic information. There are no significant differences in the prevalence of other autoantibodies associated with SSc between dcSSc and lcSSc patients.

Authors+Show Affiliations

Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin.Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin.Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25228505

Citation

Wielosz, Ewa, et al. "Serological Profile of Patients With Systemic Sclerosis." Postepy Higieny I Medycyny Doswiadczalnej (Online), vol. 68, 2014, pp. 987-91.
Wielosz E, Dryglewska M, Majdan M. Serological profile of patients with systemic sclerosis. Postepy Hig Med Dosw (Online). 2014;68:987-91.
Wielosz, E., Dryglewska, M., & Majdan, M. (2014). Serological profile of patients with systemic sclerosis. Postepy Higieny I Medycyny Doswiadczalnej (Online), 68, 987-91. https://doi.org/10.5604/17322693.1117543
Wielosz E, Dryglewska M, Majdan M. Serological Profile of Patients With Systemic Sclerosis. Postepy Hig Med Dosw (Online). 2014 Aug 18;68:987-91. PubMed PMID: 25228505.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serological profile of patients with systemic sclerosis. AU - Wielosz,Ewa, AU - Dryglewska,Magdalena, AU - Majdan,Maria, Y1 - 2014/08/18/ PY - 2014/9/18/entrez PY - 2014/9/18/pubmed PY - 2015/6/27/medline SP - 987 EP - 91 JF - Postepy higieny i medycyny doswiadczalnej (Online) JO - Postepy Hig Med Dosw (Online) VL - 68 N2 - INTRODUCTION: The systemic sclerosis-associated autoantibodies include anti-centromere, anti-topoisomerase I (anti-topo I), anti-RNA polymerase III, anti-fibrillarin, anti-Th/To, and anti-PDGFR. A specific serological profile is connected with clinical manifestations and prognosis in systemic sclerosis (SSc). OBJECTIVES: The aim of the study was to assess the serological profile in limited cutaneous and diffuse cutaneous SSc (lcSSc and dcSSc). PATIENTS AND METHODS: 87 (68 female and 19 male) consecutive SSc patients treated between 2006 and 2011 were assessed. Patients fulfilled the American College of Rheumatology classification criteria of SSc: 35 - dcSSc and 52 - lcSSc. The following marker antibodies were determined: anti-topo I, anti-centromere A and B (CENP A, CENP B), anti-RNA polymerase III (RP11, RP 155), anti-fibrillarin (U3RNP), anti- -NOR90, anti-Th/To, anti-PM-Scl-100, anti-PM-Scl-75, anti-Ku, anti-Ro-52, anti-PDGFR. The presence of antibodies was assessed using a test - EUROLINE Systemic Sclerosis Profile. RESULTS: 82 patients (94%) had positive antinuclear antibodies; anti-topo I - 29 patients; anti-CENP-A - 20 and anti-CENP-B - 20; anti-RP11 - 9 and anti-RP155 - 7; anti-U3RNP - 1; anti-NOR90 - 6; anti-Th/ To - 3; anti-PM-Scl-100 - 7; anti-PM-Scl-75 - 11; anti-Ku - 5; anti-Ro-52 - 23 patients. We found significant differences in prevalence of anti-topo I: 25/35 vs. 4/52 p=0.0000; anti-CENP A: 0/35 vs. 20/52 p=0.0001; anti-CENP B: 0/35 vs. 20/52 p=0.0001 between dcSSc and lcSSc. CONCLUSIONS: Some antibodies in SSc, e.g. anti-topo I and anti-centromere, are useful in defining the clinical subset of disease and provide prognostic information. There are no significant differences in the prevalence of other autoantibodies associated with SSc between dcSSc and lcSSc patients. SN - 1732-2693 UR - https://www.unboundmedicine.com/medline/citation/25228505/Serological_profile_of_patients_with_systemic_sclerosis_ L2 - http://www.phmd.pl/fulltxt.php?ICID=1117543 DB - PRIME DP - Unbound Medicine ER -